Abtin et al. recently successfully tested an exogenous siRNA-based therapy to inhibit the highly overexpressed circ_0009910/miR-145-5p/MUC1 axis in invasive HER2-negative BC metastasizing into lymph nodes [216]. Here, ERBB2 is linked to breast cancer.